More bronchiectasis patients benefit from macrolides
Long-term use of macrolides for bronchiectasis can reduce and delay exacerbations and improve quality of life even in patients currently excluded in guidelines, a meta-analysis shows.
Data for individual participants in three high-quality randomised controlled trials comparing at least three months of a macrolide use with placebo was reanalysed – effectively making a larger randomised controlled trial with 341 participants.
One of the studies included was the Australian BLESS trial of erythromycin vs placebo. The other two trials, including